Nitrofurantoin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Nitrofurantoin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
66
Registered trials
16
Result records
119
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Nitrofurantoin can convert its Small molecule drug profile and DNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Nitrofurantoin (query alias: nitrofurantoin) |
|---|---|
| Modality / target | Small molecule drug; DNA; DNA inhibitors |
| Highest global status | Approved |
| Originator | Procter & Gamble Co. |
| Active developers | Nova Pharmaceuticals Australasia Pty Ltd., Almatica Pharma LLC, Casper Pharma LLC |
The MCP disease footprint includes Cystitis, Prostatitis, Pyelitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTRI/2025/12/099670 | Phase 2 | Not Yet Recruiting | 50 | Not disclosed |
| CTRI/2025/11/097910 | Phase 2 | Not Yet Recruiting | 50 | Not disclosed |
| NCT07648290 | Early Phase 1 | Not yet recruiting | 260 | Healthcare utilization |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial
Phase 4; n=768; evaluation: Negative. Reported fields: Clinical resolution(7-day) = 70.0 % ; Clinical resolution(7-day) = 67.0 % ; Clinical resolution(7-day) = 59.0 %
A Phase III, Multicenter, Randomized, Active Reference, Double Blind, Double-dummy Study in Japanese Female Participants to Evaluate the Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Phase 3; n=380; evaluation: not stated. Reported fields: -; -; Therapeutic Success = 69 Participants
Twice-Daily Nitrofurantoin Administration Following Short-term Transurethral Catheterization After Pelvic Reconstructive Surgery: A Randomized Clinical Trial.
Phase 4; n=164; evaluation: Negative. Reported fields: Medication Adherence = 86.4 % ; Medication Adherence = 91.5 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Nitrofurantoin addresses Cystitis, Prostatitis, Pyelitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 119 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: DNA records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-05-26 | Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe | Approved | Financial terms not disclosed |
| 2026-03-12 | 梯瓦医药与南京正大维康达成战略合作，携手提升存达®在华可及性，进一步满足临床用药需求 | Approved | Financial terms not disclosed |
| 2025-12-22 | Handok signs Korea distribution deal for two Sanofi cancer drugs | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Preparation method of nitrofurantoin with low furacilin content”. The milestone feed surfaced a patent-application signal described as “Nitrofurantoin oral dosage form”. The milestone feed surfaced a patent-application signal described as “Method for producing nitrofurantoin anhydrate, and product thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
